Topics

Regeneron’s Yancopoulos is still bitter over Praluent sales. Can Novartis do better? https://www.statnews.com/2020/01/15/regenerons-yancopoulos-is-still-bitter-over-praluent-sales-can-novartis-do-better/ … via @statnews

11:35 EST 15 Jan 2020 | STAT

Regeneron’s Yancopoulos is still bitter over Praluent sales. Can Novartis do better? https://www.statnews.com/2020/01/15/regenerons-yancopoulos-is-still-bitter-over-praluent-sales-can-novartis-do-better/ … via

Original Article: Regeneron’s Yancopoulos is still bitter over Praluent sales. Can Novartis do better? https://www.statnews.com/2020/01/15/regenerons-yancopoulos-is-still-bitter-over-praluent-sales-can-novartis-do-better/ … via @statnews

NEXT ARTICLE

More From BioPortfolio on "Regeneron’s Yancopoulos is still bitter over Praluent sales. Can Novartis do better? https://www.statnews.com/2020/01/15/regenerons-yancopoulos-is-still-bitter-over-praluent-sales-can-novartis-do-better/ … via @statnews"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...